Helix Biopharma Corp
TSX:HBP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Helix Biopharma Corp
Cash from Operating Activities
Helix Biopharma Corp
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Helix Biopharma Corp
TSX:HBP
|
Cash from Operating Activities
-CA$3.7m
|
CAGR 3-Years
14%
|
CAGR 5-Years
18%
|
CAGR 10-Years
8%
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Cash from Operating Activities
-CA$8.7m
|
CAGR 3-Years
14%
|
CAGR 5-Years
-98%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Cash from Operating Activities
$135.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Cash from Operating Activities
-$279.1m
|
CAGR 3-Years
-42%
|
CAGR 5-Years
-42%
|
CAGR 10-Years
-31%
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Cash from Operating Activities
-CA$28.6m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-135%
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Cash from Operating Activities
-$99.2m
|
CAGR 3-Years
-78%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Helix Biopharma Corp
Glance View
Helix BioPharma Corp. is an immuno-oncology company, which develops products for the treatment and prevention of cancer. The company is headquartered in Richmond Hill, Ontario and currently employs 10 full-time employees. Helix’s proprietary technological platforms include DOS47, V-DOS47 and L-DOS47. The DOS47 is an oncology platform that offers a debilitation and destruction of cancer cells by modulating the tumor microenvironment. DOS47 is designed to stimulate an increase in the pH of the microenvironment surrounding the cancerous cells, effectively reversing the acidic extracellular conditions that are believed to act to defend the tumor. L-DOS47 is an antibody protein conjugate where the urease component enzymatically converts naturally occurring urea to ammonia. The L-DOS47 drug molecule includes a specialized camelid-derived single domain antibody. V-DOS47 targets the vascular endothelial growth factor two receptor (VEGFR2) and can be used in several types of solid tumors.
See Also
What is Helix Biopharma Corp's Cash from Operating Activities?
Cash from Operating Activities
-3.7m
CAD
Based on the financial report for Jan 31, 2026, Helix Biopharma Corp's Cash from Operating Activities amounts to -3.7m CAD.
What is Helix Biopharma Corp's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
8%
Over the last year, the Cash from Operating Activities growth was -1%. The average annual Cash from Operating Activities growth rates for Helix Biopharma Corp have been 14% over the past three years , 18% over the past five years , and 8% over the past ten years .
